By Matthew Makowski The coronavirus pandemic has ground businesses across the country to a halt.
But the best biotech IPOs and firms have been stomping on the gas pedal. And those who took the leap of faith and invested in them early have been rewarded handsomely.
In June alone, there were no less than 14 IPOs in the sector. And a good chunk of them are outperforming the broader markets.
When Pliant Therapeutics (Nasdaq: PLRX) IPOed, it was fetching $16 per share. Share prices have since jumped close to 70% in less than a month of trading.
Forma Therapeutics (Nasdaq: FMTX), which develops therapies for rare diseases …read more
